Straits Times Index
3,139.76 -43.52 (-1.37%) S&P 500
3,932.16 +15.52 (+0.40%) Dow
32,202.32 +340.34 (+1.07%) Nasdaq
11,579.18 -51.34 (-0.44%) BTC-USD
27,826.41 +568.26 (+2.08%) CMC Crypto 200
605.41 +5.74 (+0.96%)
Invitae Corporation (0JDB.L)
- Motley Fool
Invitae (NVTA) Q4 2022 Earnings Call Transcript
Joining us today are president and CEO, Ken Knight; and our CFO, Roxi Wen. Before we begin, I'd like to remind you that various remarks that we make on this call that are not historical including those about our vision and business model, the company's strategic business realignment, future financial and operating results; expectations of future growth and reduction in burn rates, expectations regarding the exchange and equitization of existing notes and extension of debt maturity and future products, services and our product pipeline and the timing.
- Zacks
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
Down 78% in 1 Year, Is There Any Hope Left for Invitae?
With shares down by 91% in the last three years, and 78% in the last 12 months alone, Invitae (NYSE: NVTA) and its investors are bound to be feeling the burn. The genetic testing company's downward spiral led Wall Street analysts to downgrade the stock, and many are suggesting that shareholders quit their positions. Let's explore how realistic it is for Invitae to make a comeback so that you'll know whether the odds are in your favor.
